In the News

Incysus submits investigational new drug (IND) application for allogeneic gamma-Delta T Cell immunotherapy for leukemia and lymphoma

by Traci Bratton

September 26, 2017
Print
Email

“On behalf of the company, I would like to thank our scientific advisors and all of our collaborators at the UAB who helped prepare and submit this IND."

http://www.tmcnet.com/usubmit/2017/09/19/8614648.htm

back to top

Media Policy Guidelines

Marketing and Communications

UAB Home

The University of Alabama at Birmingham

1720 2nd Ave South

Birmingham, AL 35294

Public Relations: (205) 934-3884

Media Specialist On Call: (205) 934-3411

Contact UAB
|
|
A-Z Site Index
|
Privacy
|
Terms of Use
|

UAB is an Equal Employment/Equal Educational Opportunity Institution dedicated to providing equal opportunities and equal access to all individuals regardless of race, color, religion, ethnic or national origin, sex (including pregnancy), genetic information, age, disability, religion, sexual orientation, gender identity, gender expression, and veteran’s status. As required by Title IX, UAB prohibits sex discrimination in any education program or activity that it operates. Individuals may report concerns or questions to UAB’s Assistant Vice President and Senior Title IX Coordinator. The Title IX notice of nondiscrimination is located at uab.edu/titleix.